



RenalGuard Therapy®

Enabling complex life-saving interventional procedures while protecting the kidneys.



Is Contrast Associated-AKI a problem?

14%	Of Cath-Lab patients suffer from CA-AKI ¹
2.5×	Higher risk of 30-day in-hospital mortality ¹
1.5×	Higher risk of readmission ¹
3.7 days	Longer average hospital stay ²

Download the AKI Risk Calculator App to see what patients are at risk



What are the underlying causes of contrast associated-AKI?



- Viscous fluid blocks filtration and oxygen delivery
- Toxic to nephrons
- Combination impedes kidney function and kills nephrons
- Takes up to 5 days to flush contrast unaided


1. A. Prasad et. Al. Contemporary Trend of acute kidney injury incidence and incremental cost among us patient undergoing percutaneous coronary procedures Catheter Cardiovasc Interv. Feb. 20, 2020;96:1184-1197.

2. Subramanian S et al. Economic burden of contrast-induced nephropathy: implications for prevention strategies. Journal of Medical Economics. 2007;10(2):119-134.

RenalGuard Therapy is the first clinically validated solution to prevent CA-AKI

Enables real-time patient-tailored matched hydration therapy as per ESC Guidelines*

- Flushes harmful nephrotoxins
- Manages intravascular volume
- Maintains adequate renal perfusion
- May reduce oxidative stress



Start therapy 1 hour before, continue during, and finish 4 hours after procedure

Easy to set up and operate

- Integrates into current clinical workflow
- Reduces the need for perioperative or overnight hydration
- Simple, nurse-operated system, allows physician to focus on the procedure

*Forced diuresis with matched rehydration as a protection against contrast-induced nephropathy has been endorsed in the European Society of Cardiology guidelines [\[Link\]](#).

79% Reduction

Remedial II Study: Patients treated with RenalGuard had a 79% lower rate of CA-AKI when compared to the standard of care¹

MYTHOS Study: Patients treated with RenalGuard demonstrated a 74% lower incidence of CA-AKI when compared to those receiving standard hydration²


74% Reduction

45% Reduction

Remedial III Study: RCT of 709 patients, those treated with RenalGuard had a 45% lower incidence of CA-AKI when compared to patients receiving the Poseidon Protocol, a hydration protocol base upon LVEDP.³

RenalGuard Therapy® is the first clinically validated solution to prevent CA-AKI

1,455 combined patients with positive results in peer-reviewed, prospective studies



Demonstrated long-term value of RenalGuard in 12-month follow-up (AKI-GUARD Study)

72% lower incidence of AKI
(from 25% to 7%)

~80% fewer hospitalization days
(from 4.9 to 1 day on average)

80% lower incidence of MACCE
(from 32% to 7%)

1. C. Briguori et. al. Circulation, 2011 Sep 13;124(11):1260-9.
2. Marenzi et. al. JACC: Cardiovascular Interventions Volume 5, Issue 1, Jan. 2012, Pages 90-97
3. C. Briguori et. al. CCI, Volume 95, Issue 5, July 2019 April 1, 2020, 895-903



Manufacturer:

CardioRenal Systems INC.
459 Fortune Boulevard, Milford, MA 01757
Tel: (508) 541-8800 info@RenalGuard.com
Cleared for Balanced Fluid Management
BR00069 Rev. A



0044

Distributed by:



www.renalguard.com